$FOLD
AMICUS THERAPEUTICS, INC.

2023 Q4 Form 10-Q Financial Statement

#000117887923000016 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $115.1M $103.5M
YoY Change 30.63% 26.7%
Cost Of Revenue $11.32M $9.946M
YoY Change 20.67% -25.97%
Gross Profit $103.8M $93.56M
YoY Change 31.82% 37.07%
Gross Profit Margin 90.16% 90.39%
Selling, General & Admin $70.24M $65.65M
YoY Change 29.42% 38.88%
% of Gross Profit 67.7% 70.17%
Research & Development $35.03M $40.70M
YoY Change -45.16% -23.16%
% of Gross Profit 33.76% 43.51%
Depreciation & Amortization $2.182M $2.228M
YoY Change 66.44% 73.25%
% of Gross Profit 2.1% 2.38%
Operating Expenses $107.4M $110.6M
YoY Change -11.23% 8.31%
Operating Profit -$3.692M -$17.02M
YoY Change -91.28% -49.7%
Interest Expense -$11.16M $12.99M
YoY Change 22.28% 34.99%
% of Operating Profit
Other Income/Expense, Net -$2.879M $3.833M
YoY Change -84.54% -71.89%
Pretax Income -$31.66M -$24.71M
YoY Change -54.82% -15.58%
Income Tax $2.183M -$3.128M
% Of Pretax Income
Net Earnings -$33.84M -$21.58M
YoY Change -39.42% -35.18%
Net Earnings / Revenue -29.41% -20.85%
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$0.11 -$0.07
COMMON SHARES
Basic Shares Outstanding 293.2M shares 287.1M shares
Diluted Shares Outstanding 295.8M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $286.2M $280.3M
YoY Change -2.52% -20.98%
Cash & Equivalents $247.0M $263.3M
Short-Term Investments $39.21M $17.00M
Other Short-Term Assets $49.53M $52.70M
YoY Change 23.19% 37.73%
Inventory $59.70M $56.94M
Prepaid Expenses
Receivables $87.63M $73.33M
Other Receivables $0.00 $0.00
Total Short-Term Assets $483.1M $463.3M
YoY Change 13.98% 1.03%
LONG-TERM ASSETS
Property, Plant & Equipment $31.67M $31.07M
YoY Change 2.89% -4.24%
Goodwill $197.8M $197.8M
YoY Change 0.0% 0.0%
Intangibles $20.50M $21.32M
YoY Change -10.87% -7.31%
Long-Term Investments
YoY Change
Other Assets $18.55M $21.13M
YoY Change -3.58% 18.23%
Total Long-Term Assets $294.8M $300.8M
YoY Change -1.84% -0.05%
TOTAL ASSETS
Total Short-Term Assets $483.1M $463.3M
Total Long-Term Assets $294.8M $300.8M
Total Assets $777.9M $764.1M
YoY Change 7.42% 0.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.12M $23.15M
YoY Change -1.9% 92.21%
Accrued Expenses $152.6M $146.3M
YoY Change 49.3% 10.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $167.7M $169.5M
YoY Change 20.62% 2.92%
LONG-TERM LIABILITIES
Long-Term Debt $387.9M $394.1M
YoY Change -1.05% 0.71%
Other Long-Term Liabilities $13.28M $8.962M
YoY Change 48.58% 10.02%
Total Long-Term Liabilities $13.28M $8.962M
YoY Change 48.58% 10.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $167.7M $169.5M
Total Long-Term Liabilities $13.28M $8.962M
Total Liabilities $617.7M $630.8M
YoY Change 2.76% 0.62%
SHAREHOLDERS EQUITY
Retained Earnings -$2.700B -$2.700B
YoY Change 8.0% 8.0%
Common Stock $2.839B $2.790B
YoY Change 6.42% 5.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $160.2M $133.2M
YoY Change
Total Liabilities & Shareholders Equity $777.9M $764.1M
YoY Change 7.42% 0.6%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$33.84M -$21.58M
YoY Change -39.42% -35.18%
Depreciation, Depletion And Amortization $2.182M $2.228M
YoY Change 66.44% 73.25%
Cash From Operating Activities $3.458M -$38.35M
YoY Change -104.28% 229.86%
INVESTING ACTIVITIES
Capital Expenditures $1.731M $1.570M
YoY Change -35.34% 1045.99%
Acquisitions
YoY Change
Other Investing Activities -$22.23M $37.33M
YoY Change -65.29% -49.81%
Cash From Investing Activities -$23.96M $35.76M
YoY Change -64.08% -52.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.210M 37.62M
YoY Change 1373.97% -6829.87%
NET CHANGE
Cash From Operating Activities 3.458M -38.35M
Cash From Investing Activities -23.96M 35.76M
Cash From Financing Activities 8.210M 37.62M
Net Change In Cash -12.29M 35.03M
YoY Change -91.64% -43.8%
FREE CASH FLOW
Cash From Operating Activities $3.458M -$38.35M
Capital Expenditures $1.731M $1.570M
Free Cash Flow $1.727M -$39.92M
YoY Change -102.07% 239.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
394071000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
391990000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
52454000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
51578000 usd
CY2023Q3 us-gaap Deferred Credits And Other Liabilities Noncurrent
DeferredCreditsAndOtherLiabilitiesNoncurrent
5906000 usd
CY2022Q4 us-gaap Deferred Credits And Other Liabilities Noncurrent
DeferredCreditsAndOtherLiabilitiesNoncurrent
4656000 usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4939000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8962000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8939000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
630847000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
601120000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
290667041 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
290667041 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2890000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2815000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2787275000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-195000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-116000 usd
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
71000 usd
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
83000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2650231000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2532490000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
133237000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
123047000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
764084000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
724167000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103501000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81691000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
284274000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
241137000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9946000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13436000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
26002000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
93555000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
68255000 usd
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
40704000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
158767000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-2583000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
506000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
1134000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
6616000 usd
us-gaap Interest Expense
InterestExpense
26024000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13007000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22804000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-118441000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-171960000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-700000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8743000 usd
us-gaap Net Income Loss
NetIncomeLoss
-117741000 usd
us-gaap Net Income Loss
NetIncomeLoss
-180703000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
288841092 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
288841092 shares
us-gaap Net Income Loss
NetIncomeLoss
-117741000 usd
us-gaap Net Income Loss
NetIncomeLoss
-180703000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
5416000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-43975000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-79000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-84000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5337000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-44059000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-112404000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-224762000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
111581000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3442000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-2347000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16511000 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
20339000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1032000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
248000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
50000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
14.39
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
21417000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7765000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8552000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
169454000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
139018000 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
281108273 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
281108273 shares
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2664744000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-6573000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-11989000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5691000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4031000 usd
us-gaap Operating Expenses
OperatingExpenses
331791000 usd
us-gaap Operating Expenses
OperatingExpenses
381714000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-73519000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-169792000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
5407000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1052000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
12986000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
9620000 usd
us-gaap Interest Expense
InterestExpense
37322000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
295759435 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
295759435 shares
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-18000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-10910000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-21577000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
133237000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
123047000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7847000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-16355000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
67982000 usd
fold Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
12000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-79000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
5416000 usd
us-gaap Net Income Loss
NetIncomeLoss
-117741000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
133237000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
173425000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
16355000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
11119000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7847000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3191000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1333000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-1841000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14772000 usd
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
283000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-22121000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-33286000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
132565000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
307369000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3191000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-11119000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
57886000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-84000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-43975000 usd
us-gaap Net Income Loss
NetIncomeLoss
-180703000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
132565000 usd
us-gaap Profit Loss
ProfitLoss
-117741000 usd
us-gaap Profit Loss
ProfitLoss
-180703000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2080000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1963000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5691000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4031000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
67982000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
57886000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2583000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-506000 usd
fold Foreign Currency Remeasurement Gain Loss Before Tax
ForeignCurrencyRemeasurementGainLossBeforeTax
-18121000 usd
fold Foreign Currency Remeasurement Gain Loss Before Tax
ForeignCurrencyRemeasurementGainLossBeforeTax
-2828000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-4939000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
fold Asset Impairment Charges And Other Asset Write Offs
AssetImpairmentChargesAndOtherAssetWriteOffs
2360000 usd
fold Asset Impairment Charges And Other Asset Write Offs
AssetImpairmentChargesAndOtherAssetWriteOffs
17271000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8614000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7426000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
42233000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4913000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
26010000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5583000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
41101000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
25465000 usd
fold Increase Decrease In Noncurrent Operating Liabilities
IncreaseDecreaseInNoncurrentOperatingLiabilities
-4993000 usd
fold Increase Decrease In Noncurrent Operating Liabilities
IncreaseDecreaseInNoncurrentOperatingLiabilities
-5942000 usd
us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
7937000 usd
us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-72549000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85803000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
180828000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
259920000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
53098000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
99811000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5709000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1089000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
122021000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
159020000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
82000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
92000 usd
fold Proceeds From The Issuance Of Shares In Connection With At The Market Offering Net Of Issuance Costs
ProceedsFromTheIssuanceOfSharesInConnectionWithAtTheMarketOfferingNetOfIssuanceCosts
63108000 usd
fold Proceeds From The Issuance Of Shares In Connection With At The Market Offering Net Of Issuance Costs
ProceedsFromTheIssuanceOfSharesInConnectionWithAtTheMarketOfferingNetOfIssuanceCosts
0 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1063000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53467000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8020000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10218000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-33120000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
113157000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32077000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
266272000 usd
us-gaap Interest Paid Net
InterestPaidNet
35448000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6473000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
935000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2700000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable primarily related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span>. The Company's accounts receivable at September 30, 2023 have arisen from product sales primarily in Europe, the U.S., and Japan. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
100000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
241137000 usd
CY2022Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
293595000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148813000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
148813000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
144700000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
82000 usd
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P7Y
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1700000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2500000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3300000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263300000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
17000000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263320000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
263320000 usd
CY2022Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities
CashCashEquivalentsAndAvailableforsaleDebtSecurities
293513000 usd
CY2022Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
82000 usd
CY2022Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
144782000 usd
CY2022Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities
CashCashEquivalentsAndAvailableforsaleDebtSecurities
293513000 usd
CY2022Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
82000 usd
CY2022Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2022Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
293595000 usd
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
CY2022 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263320000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
277592000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2952000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3941000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
266272000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
281533000 usd
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
36062000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
10054000 usd
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
14316000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
9615000 usd
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6558000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4147000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
56936000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
23816000 usd
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
300000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
400000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
394071000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
391990000 usd
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
12270000 usd
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
411000 usd
CY2023Q3 fold Amortization Deferred Financing Costs
AmortizationDeferredFinancingCosts
310000 usd
fold Sale Of Stock Weighted Average Price
SaleOfStockWeightedAveragePrice
12.50
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19064000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5522000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.03
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
23256000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.64
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
32100000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
21389000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.58
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y6M
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
31100000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
13246000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
27900000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16511000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14772000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67982000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
57886000 usd
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
23647000 usd
CY2023Q3 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
6718000 usd
CY2023Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
6718000 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
150189000 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
21417000 usd
CY2022Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
5458000 usd
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
26875000 usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
13005000 usd
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
19266000 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
21417000 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1995000 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-567000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-2583000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
506000 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
15000000 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
24000000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
19833000 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
19833000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-21577000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-33286000 usd
us-gaap Net Income Loss
NetIncomeLoss
-117741000 usd
us-gaap Net Income Loss
NetIncomeLoss
-180703000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
295759435 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
295759435 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
289223709 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
289223709 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
293314167 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
293314167 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
288841092 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
288841092 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33587000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29075000 shares
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001178879-23-000016-index-headers.html Edgar Link pending
0001178879-23-000016-index.html Edgar Link pending
0001178879-23-000016.txt Edgar Link pending
0001178879-23-000016-xbrl.zip Edgar Link pending
exhibit103-simonharfordemp.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fold-09302023xex311.htm Edgar Link pending
fold-09302023xex312.htm Edgar Link pending
fold-09302023xex321.htm Edgar Link pending
fold-20230930.htm Edgar Link pending
fold-20230930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
fold-20230930_def.xml Edgar Link unprocessable
fold-20230930_lab.xml Edgar Link unprocessable
fold-20230930_pre.xml Edgar Link unprocessable
fold-20230930_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
fold-20230930_cal.xml Edgar Link unprocessable